Literature DB >> 19371868

Bosentan reduces oxidative burst in acid aspiration-induced lung injury in rats.

Benedikt Trabold1, Michael Pawlik, Renata Nietsch, Diane I Bitzinger, Michael Gruber, Karl-Peter Ittner, Matthias Lubnow.   

Abstract

BACKGROUND: Acid aspiration induces lung injury by causing an intense inflammatory reaction. Neutrophils are attracted by various cytokines, such as TNFbeta, and release reactive oxygen species, which then cause acute lung injury. Endothelin antagonists, such as bosentan, have been found to possess anti-inflammatory properties.
MATERIALS AND METHODS: We performed a prospective, randomised, controlled study to evaluate the effects of bosentan in a rat model of acid-induced lung injury. Sprague-Dawley rats underwent sevoflurane anaesthesia; lung injury was then induced by instillation of 1.2mL/kg, 0.1M hydrochloric acid. The lungs were ventilated for 6h and then randomised into three groups: bosentan 30mg/kg body weight, 90mg/kg body weight or sodium chloride, each applied immediately after acid aspiration via a gastric tube.
RESULTS: After induction of acute lung inflammation, the production of reactive oxygen species by PMN following stimulation with FMLP increased significantly. Comparison of pre-treatment and post-treatment in the 90mg/kg bosentan treatment group did not show a significant increase of reactive oxygen species following stimulation with FMLP. A comparison of the absolute difference of the MESF demonstrated a significant difference between the control group and the group treated with 90mg/kg bosentan.
CONCLUSIONS: Bosentan administration at 90mg/kg body weight reduced the release of reactive oxygen species after 360min in acid aspiration-induced lung injury in rats.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371868     DOI: 10.1016/j.injury.2008.11.016

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  7 in total

1.  Time course of metabolic activity and cellular infiltration in a murine model of acid-induced lung injury.

Authors:  Vanessa Zambelli; Giuseppe Di Grigoli; Margherita Scanziani; Silvia Valtorta; Maria Amigoni; Sara Belloli; Cristina Messa; Antonio Pesenti; Ferruccio Fazio; Giacomo Bellani; Rosa Maria Moresco
Journal:  Intensive Care Med       Date:  2012-01-26       Impact factor: 17.440

Review 2.  Endothelin-1 and its role in the pathogenesis of infectious diseases.

Authors:  Brandi D Freeman; Fabiana S Machado; Herbert B Tanowitz; Mahalia S Desruisseaux
Journal:  Life Sci       Date:  2014-04-26       Impact factor: 5.037

Review 3.  Current Pharmacological Approach to ARDS: The Place of Bosentan.

Authors:  Omer Araz
Journal:  Eurasian J Med       Date:  2020-02

4.  Using bosentan to treat paraquat poisoning-induced acute lung injury in rats.

Authors:  Zhongchen Zhang; Xiangdong Jian; Wei Zhang; Jieru Wang; Qian Zhou
Journal:  PLoS One       Date:  2013-10-14       Impact factor: 3.240

5.  Comparison of reducing effect on lung injury of dexamethasone and bosentan in acute lung injury: an experimental study.

Authors:  Omer Araz; Elif Demirci; Elif Yilmazel Ucar; Muhammet Calik; Didem Pulur; Adem Karaman; Muhammed Yayla; Eren Altun; Zekai Halici; Metin Akgun
Journal:  Multidiscip Respir Med       Date:  2013-12-17

6.  Unexpected Favourable Course of Coronavirus Disease 2019 in Chronic Thromboembolic Pulmonary Hypertension Patients.

Authors:  Teresa Segura de la Cal; Jorge Nuche; Carmen Jiménez López-Guarch; Carmen Pérez-Olivares; Maite Velázquez; Francisco López-Medrano; María Jesús López Gude; Sergio Alonso Charterina; Fernando Arribas Ynsaurriaga; Pilar Escribano Subías
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2020-06-26       Impact factor: 4.872

Review 7.  Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.

Authors:  Yujiro Matsuishi; Bryan J Mathis; Nobutake Shimojo; Jesmin Subrina; Nobuko Okubo; Yoshiaki Inoue
Journal:  Biomedicines       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.